Garuda Therapeutics is a biotechnology company focused on creating off-the-shelf hematopoietic stem cell therapies aimed at treating various severe and life-threatening conditions. The company specializes in addressing blood, bone marrow, immune, and metabolic diseases. By leveraging expertise in innovative research methods, including the use of zebrafish, mice, and human-induced pluripotent stem cells, Garuda analyzes novel genes and mechanisms vital for blood formation. This approach enables the development of mechanism-based therapies designed to improve patient outcomes.
Slingshot Biosciences aims to bring simple, elegant, and cost-effective solutions to common problems facing research and development programs. Our technology platform will make a significant bottom-line impact on the speed and cost of early-stage discovery, research and development programs.
Elephas is a live tumor imaging diagnostics company focused on enhancing cancer treatment through personalized therapy determination. The company leverages advancements in cancer biology, multimodal microscopy, engineering, and artificial intelligence to analyze human live tumor fragments. This innovative platform aims to improve clinical decision-making for oncologists, enabling them to tailor treatments to individual patients. Additionally, Elephas seeks to accelerate drug development processes, addressing the urgent need for effective cancer therapies in a rapidly evolving healthcare landscape.
CAMP4 Therapeutics Corporation is a bioinformatics company based in Cambridge, Massachusetts, founded in 2015. The company specializes in gene regulation circuitry, utilizing a 4-D gene circuitry platform to codify the activation of the over 24,000 genes in the human body into a set of combinatorial rules. This approach allows CAMP4 to manipulate gene production through existing cellular signaling pathways, directly addressing the fundamental causes of diseases. By leveraging machine learning algorithms, the platform simplifies the drug discovery process, enabling the identification of druggable targets and facilitating a quicker and less risky path to developing new medicines. This innovative methodology significantly accelerates the initiation of disease treatment, ultimately benefiting patients by reducing the time required to bring new therapies to market.
Molecule GmbH is a company that has developed a virtual accelerator platform aimed at facilitating the translation of scientific discoveries into new therapeutics. Founded in 2018 and headquartered in Neuhausen am Rheinfall, Switzerland, with an additional office in Berlin, Germany, Molecule connects scientists with the necessary funding for therapeutic development. This platform also links private investors directly with scientists, promoting the advancement of various treatments for patients. By streamlining the innovation process within the pharmaceutical industry, Molecule seeks to enhance the efficiency of bringing novel therapeutics to market.
Vizgen, Inc. is a biotechnology company that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. The company's flagship technology, MERFISH, utilizes multiplexed single-molecule imaging to accurately measure the quantity and spatial distribution of RNA within individual cells. This innovative approach facilitates single-cell gene expression profiling in intact tissue slices, providing valuable insights into various applications, including oncology, immunology, neuroscience, infectious disease, and regenerative medicine. Established in 2019 and based in Cambridge, Massachusetts, Vizgen is committed to advancing research by enabling high-throughput and cost-effective analysis of complex biological systems at a cellular level.
Transition Bio, Inc. is a biotechnology company that specializes in the discovery, analysis, and modulation of biological condensates. Established in 2020 and headquartered in Cambridge, Massachusetts, with an additional office in Cambridge, United Kingdom, the company has developed a unique platform known as Condensomics. This hypothesis-free drug discovery and diagnostics technology allows for expansive opportunities in drug development by leveraging the intricate properties of biological condensates. Transition Bio's innovative approach aims to advance the understanding and application of these biological structures in the field of medicine.
OMass Technologies Ltd engages in drug discovery by applying mass spectrometry to the characterization of intact protein assemblies. The company offers biotherapeutics, membrane proteins, drug binding, and purifications guiding services. In addition, OMass Technologies Ltd offers structural mass spectrometry (MS) platforms, often referred to as native mass spectrometry, for characterizing complex protein assemblies. The company assists biotechnology and pharmaceutical companies in tackling drug targets and biotherapeutics. OMass Technologies Ltd was founded in 2016 and is based in Begbroke, United Kingdom.
Ansa Biotechnologies, Inc. is a biotechnology company based in Berkeley, California, focused on developing innovative DNA synthesis technology utilizing enzymes. Established in 2018, the company aims to improve upon traditional chemical methods of DNA synthesis that have remained largely unchanged for decades. Ansa's enzymatic approach offers significant advantages, including increased speed, accuracy, and cleanliness in the production of DNA fragments such as oligonucleotides. This technology enhances the capabilities of biological research, therapeutics, diagnostics, and biomanufacturing by enabling the synthesis of gene-length oligonucleotides. Through its advancements, Ansa Biotechnologies seeks to facilitate innovation in the fields of biological research and engineering, ultimately providing valuable services to medical researchers and contributing to the broader biotechnology landscape.
Eleanor Health Holdings, LLC is a provider of rehabilitation services focused on addiction and mental health care. Founded in 2019, the company offers comprehensive, evidence-based outpatient care designed to facilitate long-term recovery outcomes. Eleanor Health utilizes a value-based care model, delivering services through a network of outpatient clinics, virtual platforms, and community settings, including patients' homes. Its integrated approach includes medication-assisted treatment, behavioral health support, and personalized recovery plans. In addition to rehabilitation services, the company connects patients with essential resources such as housing, employment, and peer support, ensuring a holistic approach to recovery. Eleanor Health is headquartered in Waltham, Massachusetts.
Triumvira Immunologics is an immunotherapy company focused on developing innovative T cell therapies for cancer treatment. Founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada, the company specializes in chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Its proprietary T cell Antigen Coupler (TAC) technology enhances the natural T cell receptor's capabilities and operates independently of the major histocompatibility complex. This unique approach aims to create more effective therapies for a diverse group of patients suffering from both solid and liquid tumors, as well as other diseases. Triumvira's commitment to advancing cancer treatment reflects its mission to improve patient outcomes with safer and more effective therapeutic options.
DNAnexus, Inc. specializes in cloud-based genome informatics and data management tools tailored for enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company provides a platform that facilitates the analysis of raw sequencing data, integrates genomic data with clinical information, and enhances collaboration among researchers. Key offerings include the MOSAIC Microbiome platform for microbiome research, DNAnexus Apollo for clinico-genomic data exploration, DNAnexus Titan for data analysis, and DNAnexus Portals, which create secure online workspaces for collaborative projects. Additionally, the Clinico-Genomic Data Solution aims to enhance disease-specific datasets through partnerships with healthcare providers, improving screening and treatment pathways for complex diseases. DNAnexus serves a diverse clientele, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.
Sherlock Biosciences, Inc., a biotechnology company, develops molecular diagnostics solutions. It offers SHERLOCK, a CRISPR-based method to detect and quantify specific genetic sequences, and INSPECTR, a synthetic biology-based molecular diagnostics platform. The company offers its products in the areas of precision oncology, infection identification, food safety, at-home tests, and disease detection. The company was incorporated in 2018 and is based in Cambridge, Massachusetts.
Operator of a digital manufacturing suite intended to design and mass-produce products whose functions and performance necessitate precision at the micron scale. The company's technology helps in bringing new product concepts and rapidly scalable production capacity to globally-recognized brands, enabling clients to develop novel product concepts and bring them successfully to commercialization.
Scipher Medicine is a biotechnology company based in Waltham, Massachusetts, that focuses on developing a molecular technology platform to predict patient responses to drug therapies, particularly in cardiovascular and autoimmune diseases. The company offers several diagnostic tests, including PrismDx, which identifies patients who may not respond to specific medications, PrismRA for patients with rheumatoid arthritis, and PrismUC for those with ulcerative colitis. These tests enable healthcare providers to prescribe more suitable alternative therapies for patients who are unlikely to benefit from traditional treatments. Scipher Medicine emphasizes the importance of providing scientifically backed data to improve patient outcomes and enhance treatment decisions. The company has also established a strategic partnership with Ambry Genetics Corporation to further advance its capabilities. Founded in 2014, Scipher Medicine was previously known as DZZOM Delaware Corporation before changing its name in 2015.
Story Health Corporation, founded in 2020 and based in Saratoga, California, develops advanced virtual clinical care software tools aimed at assisting healthcare specialists, particularly neurologists and primary care physicians. The company's platform utilizes data from high-frequency sources to enhance clinical decision-making and improve patient therapy management. By integrating virtual protocols and adaptive machine learning, Story Health empowers clinicians to bridge the gap between clinical evidence and patient realities. Its focus on patient-centered design facilitates a deeper understanding of the physiological effects of diseases and therapies, ultimately aiming to optimize patient care and outcomes in specialty healthcare settings.
Walking Fish Therapeutics is developing a platform to harness B cells’ capability to activate the immune system in the treatment of cancer, and to serve as in vivo protein factories that produce replacement proteins for deficiency diseases, regenerative proteins, and engineered antibodies.
Developer of a product life cycle management platform designed to provide a digital way to manage development processes. The company's platform collects all the teams' data and knowledge in one searchable and cloud-based hub and integrates the product, process, and quality workflows, enabling biopharma organizations to increase the probability of technical success and help get therapeutic breakthroughs to patients quickly.
1859, Inc. is a biotechnology company that specializes in the discovery and development of next-generation therapeutics. Founded in 2019, the company is headquartered in San Diego, California. Its focus on innovative healthcare solutions positions it within the evolving landscape of biotechnology, where it aims to contribute to advancements in treatment options.
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Berkeley, California, specializing in the development of cell therapies for serious autoimmune diseases. Founded in 2018, Kyverna employs advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells, addressing the root causes of inflammatory diseases. The company is advancing its therapeutic platform with product candidates such as KYV-101, an autologous CD19 CAR T-cell therapy, and KYV-201, an allogeneic version utilizing the same chimeric antigen receptor. Through these innovative approaches, Kyverna aims to provide effective treatments and potential cures for patients suffering from autoimmune conditions.
64x Bio is a biotechnology company based in San Francisco, California, founded in 2017 by Alexis Rovner, George Church, Jeffrey Way, and Pamela Silver. The company specializes in designing microorganisms with enhanced properties to facilitate advanced applications in biomanufacturing, bioremediation, and health. By creating cells tailored for specific purposes, 64x Bio aims to enable innovative solutions that were previously unattainable in these fields.
Ori Biotech is a developer of a manufacturing platform used to help patients get access to lifesaving treatments. Ori has developed a proprietary, flexible manufacturing platform that closes, automates, and standardizes manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial-scale manufacturing. The company aims to speed up the innovation of cell and gene therapies through the manufacturing platform it is bringing to market.
Scitara offers a unique cloud-based connectivity platform that transforms integration between instruments and lab informatics applications. The Scitara Cloud-based technology provides a standardized platform for communication and automated workflows lab wide. This dramatically simplifies the overall integration framework and makes automation possible where it was not possible before. The company was founded in 2019 and based in Marlborough, Massachusetts.
Developer of chemical biology technologies designed to create therapeutics for untreatable diseases. The company's technology uses the power of covalent bonding and a proprietary technology platform for high-throughput drug discovery, enabling pharmaceutical developers to convert genetic discoveries into real drugs to treat cancer, Alzheimer's, infectious diseases, and even aging.
Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.
SimBioSys, Inc. is developing a Computational Microscope that integrates state-of-the-art simulation techniques with a diverse set of experimental datasets to provide new insight into the behavior of cancers. The technology allows researchers to peer into the cancer microenvironment to identify the behavior of tumors: the cell phenotypes, how they interact with surrounding tissues, and how they prime their neighbors for invasion, all from the comfort of their computer desk.
Culture Biosciences, founded in 2016 and headquartered in San Francisco, California, specializes in developing automated bioreactors and tools for fermentation. The company provides a digital bio-manufacturing platform that allows biotech companies to optimize their manufacturing processes, enabling them to bring products to market more efficiently. By utilizing robotic sample handling and cloud-based data monitoring and analysis, Culture Biosciences helps scientists run, monitor, and analyze bioreactors more quickly than traditional methods. This innovative approach supports the biotechnology sector in enhancing productivity and streamlining workflows.
Kytopen Corp. is a biotechnology company based in Cambridge, Massachusetts, focused on advancing cell therapy through its innovative Flowfect technology. Established in 2017, Kytopen specializes in non-viral delivery systems for molecules into challenging immune cells that are typically hard to transfect. The company utilizes a combination of microfluidics and automation to streamline the delivery process, making it faster, more efficient, and cost-effective. By employing a unique platform that integrates continuous fluid flow with electric fields, Kytopen enables researchers to produce high-quality engineered cells in a matter of minutes while preserving their health and functionality. This approach supports the discovery of novel biological insights and the development of affordable cell and gene therapies.
Garuda Therapeutics is a biotechnology company focused on creating off-the-shelf hematopoietic stem cell therapies aimed at treating various severe and life-threatening conditions. The company specializes in addressing blood, bone marrow, immune, and metabolic diseases. By leveraging expertise in innovative research methods, including the use of zebrafish, mice, and human-induced pluripotent stem cells, Garuda analyzes novel genes and mechanisms vital for blood formation. This approach enables the development of mechanism-based therapies designed to improve patient outcomes.
Elephas is a live tumor imaging diagnostics company focused on enhancing cancer treatment through personalized therapy determination. The company leverages advancements in cancer biology, multimodal microscopy, engineering, and artificial intelligence to analyze human live tumor fragments. This innovative platform aims to improve clinical decision-making for oncologists, enabling them to tailor treatments to individual patients. Additionally, Elephas seeks to accelerate drug development processes, addressing the urgent need for effective cancer therapies in a rapidly evolving healthcare landscape.
Emulate, Inc. specializes in developing organs-on-chips technology that emulates human biology to better understand the effects of diseases, medications, and environmental factors on human health. The company offers organ-chips that replicate the functions of various organs, including the lung, intestine, liver, and skin, and can simulate both normal and disease states. Emulate’s platform aims to provide more accurate predictions of human responses compared to traditional experimental methods, such as cell cultures or animal testing. The company serves a diverse clientele that includes biotechnology and pharmaceutical firms, consumer health and cosmetics companies, government agencies, and academic researchers. Founded in 2013 and based in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. It has shifted its focus towards advancing product innovation and safety across multiple sectors, including drug development and personalized medicine.
DiCE Therapeutics, founded in 2013 and based in Menlo Park, California, specializes in developing a platform for the discovery of novel small molecules aimed at targets that have previously been difficult to address in the pharmaceutical sector. The company utilizes innovative technology that extends directed evolution, allowing for the direct translation of DNA-encoded information into organic compounds, thereby streamlining the traditionally labor-intensive processes of medicinal chemistry. This platform not only serves the pharmaceutical industry but also has applications in agriculture and materials sciences. The founding team includes notable figures such as Stanford Professor Pehr Harbury, who developed the core technology, and other experienced professionals from various sectors, contributing to the company's mission of transforming drug discovery and development.
Sound Agriculture Company develops innovative crop protection and enhancement products aimed at improving agricultural yields and farm revenues while addressing challenges such as drought. The company offers Source, a solution that enhances in-season nutrient uptake by unlocking existing nitrogen and phosphorus in the soil, thereby helping growers optimize crop performance sustainably. Additionally, Sound Agriculture focuses on improving photosynthesis, water capture, and crop efficiency, contributing to healthier and more flavorful food while reducing waste. Founded in 2012 and based in Emeryville, California, the company employs molecular discovery and life science approaches to create climate-resilient crops, ultimately enhancing productivity for farmers. Originally known as Asilomar Bio, Inc., it rebranded to Sound Agriculture Company in September 2018.
Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.
Slingshot Biosciences aims to bring simple, elegant, and cost-effective solutions to common problems facing research and development programs. Our technology platform will make a significant bottom-line impact on the speed and cost of early-stage discovery, research and development programs.
CAMP4 Therapeutics Corporation is a bioinformatics company based in Cambridge, Massachusetts, founded in 2015. The company specializes in gene regulation circuitry, utilizing a 4-D gene circuitry platform to codify the activation of the over 24,000 genes in the human body into a set of combinatorial rules. This approach allows CAMP4 to manipulate gene production through existing cellular signaling pathways, directly addressing the fundamental causes of diseases. By leveraging machine learning algorithms, the platform simplifies the drug discovery process, enabling the identification of druggable targets and facilitating a quicker and less risky path to developing new medicines. This innovative methodology significantly accelerates the initiation of disease treatment, ultimately benefiting patients by reducing the time required to bring new therapies to market.
Hawthorne Effect is a clinical trial data platform committed to enhancing the accessibility and convenience of clinical trials for all individuals. It achieves this through a proactive Visit Management System that strengthens the partnership between study sponsors and investigators, leveraging shared technology to ensure adherence to protocols and reduce data omissions. The platform integrates licensed healthcare professionals with advanced connected technology, facilitating decentralized clinical trials that improve efficiency and accuracy compared to traditional methods. By deploying specially trained healthcare providers, known as “HEROs,” Hawthorne Effect allows for patient visits to be conducted anywhere and at any time, thereby minimizing the risk of patients being lost to follow-up and ensuring comprehensive tracking of patient data.
Clinical protocols are scientific decisions wrapped in administrative burden. The Faro system handles the tedious work better left for a computer, freeing clinical researchers to focus on the important decisions that drive clinical value.
Torus Biosystems offers an apparatus for DNA testing for scientific and medical research purposes in the fields of consumer products, food for human beings or animals, hygienic and beauty care for human beings or animals, agriculture, horticulture, and forestry.
Isolere Bio is a biotechnology company dedicated to simplifying the purification processes for biotherapeutics, particularly monoclonal antibodies and Adeno-Associated Viruses (AAV). Co-founded with the aim of enhancing global access to these critical drugs, the company is developing innovative technology that utilizes a straightforward Tangential Flow Filtration (TFF) setup. This approach is designed to facilitate a seamless transition from laboratory-scale to industrial-scale production, thereby addressing the growing demand for effective biotherapeutics in research and diagnostics. Through its focus on streamlining bioprocessing, Isolere Bio aims to contribute significantly to advancements in the biopharmaceutical industry.
Outcomes4me Inc. is a healthcare technology company based in Cambridge, Massachusetts, founded in 2017. It has developed a free mobile application and platform designed to empower patients navigating cancer treatment and care. The platform connects patients with healthcare providers and offers personalized, expert-validated information, enabling users and their families to make informed decisions about their treatment options. Outcomes4me also provides clinical trial services and generates real-world evidence to enhance clinical decision-making and improve patient outcomes. The company's mission is to ensure that patients are actively engaged in their healthcare journey, facilitating access to tailored treatment information and resources.
Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2015. The company specializes in manufacturing reagents for tissue imaging and multiplexing detection, primarily serving the life science and biomedical research communities. Ultivue offers advanced technologies such as DNA-PAINT and DNA-Exchange, which facilitate the collection of high-resolution microscopic images. These innovations are aimed at enhancing the understanding of biological processes and medical diagnostics. The company’s products are designed for use in fluorescent microscopy-based research and are expected to have future applications in clinical diagnostics.
Current Health Limited, founded in 2014 and based in Edinburgh, United Kingdom, specializes in developing wearable healthcare devices that monitor patients' vital signs. These devices are designed to measure key health metrics such as oxygen saturation, respiration rate, pulse rate, temperature, motion, activity, and posture, allowing for the early identification of unwell patients and timely medical intervention. The company also offers a patient monitoring platform that facilitates home-based care by enabling patients to share daily activities, report symptoms, and respond to structured questionnaires for their healthcare providers. By focusing on remote patient management, Current Health aims to reduce healthcare risks and costs while enhancing patient engagement and monitoring. Formerly known as Snap40 Limited, the company rebranded in December 2018 to better reflect its mission.
VieCure built an engine to turn data into knowledge and take the world’s best thinking to clinicians and patients in real time. They codify the world’s premier cancer information in an engine that considers each patient’s unique needs and creates the most personalized comprehensive care plan. By accessing our evidence-based knowledge, oncologists can create actionable cancer patient-specific personalized treatment plans that comply with nationally-accepted standards and the latest genomic-based guidelines.
Vizgen, Inc. is a biotechnology company that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. The company's flagship technology, MERFISH, utilizes multiplexed single-molecule imaging to accurately measure the quantity and spatial distribution of RNA within individual cells. This innovative approach facilitates single-cell gene expression profiling in intact tissue slices, providing valuable insights into various applications, including oncology, immunology, neuroscience, infectious disease, and regenerative medicine. Established in 2019 and based in Cambridge, Massachusetts, Vizgen is committed to advancing research by enabling high-throughput and cost-effective analysis of complex biological systems at a cellular level.
Scipher Medicine is a biotechnology company based in Waltham, Massachusetts, that focuses on developing a molecular technology platform to predict patient responses to drug therapies, particularly in cardiovascular and autoimmune diseases. The company offers several diagnostic tests, including PrismDx, which identifies patients who may not respond to specific medications, PrismRA for patients with rheumatoid arthritis, and PrismUC for those with ulcerative colitis. These tests enable healthcare providers to prescribe more suitable alternative therapies for patients who are unlikely to benefit from traditional treatments. Scipher Medicine emphasizes the importance of providing scientifically backed data to improve patient outcomes and enhance treatment decisions. The company has also established a strategic partnership with Ambry Genetics Corporation to further advance its capabilities. Founded in 2014, Scipher Medicine was previously known as DZZOM Delaware Corporation before changing its name in 2015.
Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, established in 2016. The company specializes in developing rapid tests that analyze the immune system to address significant clinical and public health challenges, particularly in the diagnosis of acute bacterial and viral infections, as well as sepsis. Utilizing patent-pending biomarkers exclusively licensed from Stanford University, Inflammatix aims to create clinically actionable results through proprietary machine-learning algorithms. In addition to its focus on acute infections and sepsis, the company is expanding its diagnostics pipeline to include tests for tropical infections, autoimmune diseases, transplant rejection, and other medical conditions, ultimately assisting healthcare providers in making informed diagnostic decisions.
StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, specializing in the development of adeno-associated viral (AAV) vector technologies and therapeutics aimed at treating rare diseases. Founded in 2015, the company employs a unique STRucture Inspired DEsign approach that merges structural knowledge with accelerated evolution to create innovative AAV capsids. This technology is designed to evade neutralizing antibodies, thereby enhancing gene transfer efficiency. StrideBio's platform supports various gene therapy modalities, including gene addition, gene silencing, and gene editing, with applications across a range of rare genetic disorders.
Vestaron Corporation is a biotechnology company that specializes in developing, manufacturing, and selling peptide-based biologic crop protection products. Founded in 2005 and headquartered in Durham, North Carolina, with a research and development center in Kalamazoo, Michigan, Vestaron offers a range of bioinsecticides including Spear-T for thrips in vegetables and ornamentals, Spear-Lep for various fruits and vegetables, and Leprotec for field use. The company's products are designed to enhance the safety, efficacy, and sustainability of agricultural practices while being safe for humans, birds, fish, and pollinators. By utilizing peptides derived from spiders, Vestaron aims to provide innovative solutions for agriculture, animal health, and commercial pest control applications.
Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.
Scitara offers a unique cloud-based connectivity platform that transforms integration between instruments and lab informatics applications. The Scitara Cloud-based technology provides a standardized platform for communication and automated workflows lab wide. This dramatically simplifies the overall integration framework and makes automation possible where it was not possible before. The company was founded in 2019 and based in Marlborough, Massachusetts.
Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, that focuses on the early detection of cancer through non-invasive blood tests. Founded in 2018, the company utilizes advanced technologies such as artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By leveraging machine learning, Delfi develops innovative testing systems aimed at recognizing cancer-associated cell-free DNA fragments, thereby enabling healthcare professionals to detect cancer at its most treatable stage. This approach facilitates timely and effective treatment options, ultimately aiming to improve patient outcomes and recovery speed.
DiCE Therapeutics, founded in 2013 and based in Menlo Park, California, specializes in developing a platform for the discovery of novel small molecules aimed at targets that have previously been difficult to address in the pharmaceutical sector. The company utilizes innovative technology that extends directed evolution, allowing for the direct translation of DNA-encoded information into organic compounds, thereby streamlining the traditionally labor-intensive processes of medicinal chemistry. This platform not only serves the pharmaceutical industry but also has applications in agriculture and materials sciences. The founding team includes notable figures such as Stanford Professor Pehr Harbury, who developed the core technology, and other experienced professionals from various sectors, contributing to the company's mission of transforming drug discovery and development.
Encodia, Inc. engages in proteomics research and creates scalable and parallelized approaches to protein analysis. The company was founded in 2015 and is based in San Diego, California.
Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.
Octave Bioscience is an early-stage molecular diagnostics company based in Menlo Park, California, that specializes in neurodegenerative diseases, particularly multiple sclerosis. Co-founded in 2013 by Melinda Thomas and William Hagstrom, the company has developed a clinical platform that generates, analyzes, and integrates data to transform the care of neurodegenerative conditions. This platform adopts a multi-dimensional approach aimed at reducing overall healthcare costs through the optimization of medication use and healthcare services. Additionally, Octave's technology supports the pharmaceutical industry by enhancing the drug discovery process, clinical trials, and post-marketing activities through real-world evidence.
NanoView Biosciences is a biotechnology company based in Boston, Massachusetts, specializing in the characterization of extracellular vesicles, particularly exosomes. Utilizing its proprietary ExoView technology, the company provides high-throughput, cost-effective analysis solutions that facilitate the detection and multiparametric characterization of exosomes from complex biological samples such as whole blood, serum, plasma, and urine. NanoView Biosciences offers a range of products, including the ExoView R100 and ExoView Tetraspanin, as well as custom assays and sample services. The company's innovations support research and the advancement of precision medicine, enabling life science researchers to gain insights into the biological roles of exosomes as potential biomarkers for disease diagnosis, treatment, and monitoring. Founded in 2015, NanoView Biosciences is committed to enhancing the understanding of exosomes in the context of health and disease.
Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.
General Automation Lab Technologies, Inc. specializes in developing and commercializing microbiological technologies that enhance the study of bacteria and other microbes. The company offers the GALT Prospector, a high-throughput isolation and cultivation array system designed for microbial research. This platform enables scientists to access a diverse range of microbes and isolate rare or unique species, facilitating deeper insights into their functions. The applications of its microbe systems span various fields, including agriculture, human health, environmental science, and industrial processes. Established in 2014, General Automation Lab Technologies is headquartered in San Carlos, California, and aims to advance microbiome science through innovative technologies.
Developer of cell engineering and data analysis platform designed to solve problems in human health applications. The company's platform enables partners to build and deliver cells and precision engineering processes that advance cellular therapies across a broad range of human health indications, enabling healthcare providers to generate safer and more efficacious cell therapies.
Refeyn specializes in label-free single molecule imaging and mass measurement, offering advanced microscopy solutions for detecting and quantifying molecules. Their technology enables users to perform precise imaging, localization, and accurate mass determination of individual biomolecules in solution. This innovative approach serves various sectors, particularly pharmaceutical, biomedical, and research industries. Founded in 2018 and headquartered in Oxford, United Kingdom, Refeyn aims to enhance research capabilities by providing tools that facilitate a deeper understanding of molecular interactions and properties.
Ori Biotech is a developer of a manufacturing platform used to help patients get access to lifesaving treatments. Ori has developed a proprietary, flexible manufacturing platform that closes, automates, and standardizes manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial-scale manufacturing. The company aims to speed up the innovation of cell and gene therapies through the manufacturing platform it is bringing to market.
Hawthorne Effect is a clinical trial data platform committed to enhancing the accessibility and convenience of clinical trials for all individuals. It achieves this through a proactive Visit Management System that strengthens the partnership between study sponsors and investigators, leveraging shared technology to ensure adherence to protocols and reduce data omissions. The platform integrates licensed healthcare professionals with advanced connected technology, facilitating decentralized clinical trials that improve efficiency and accuracy compared to traditional methods. By deploying specially trained healthcare providers, known as “HEROs,” Hawthorne Effect allows for patient visits to be conducted anywhere and at any time, thereby minimizing the risk of patients being lost to follow-up and ensuring comprehensive tracking of patient data.
Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.
Triumvira Immunologics is an immunotherapy company focused on developing innovative T cell therapies for cancer treatment. Founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada, the company specializes in chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Its proprietary T cell Antigen Coupler (TAC) technology enhances the natural T cell receptor's capabilities and operates independently of the major histocompatibility complex. This unique approach aims to create more effective therapies for a diverse group of patients suffering from both solid and liquid tumors, as well as other diseases. Triumvira's commitment to advancing cancer treatment reflects its mission to improve patient outcomes with safer and more effective therapeutic options.
DNAnexus, Inc. specializes in cloud-based genome informatics and data management tools tailored for enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company provides a platform that facilitates the analysis of raw sequencing data, integrates genomic data with clinical information, and enhances collaboration among researchers. Key offerings include the MOSAIC Microbiome platform for microbiome research, DNAnexus Apollo for clinico-genomic data exploration, DNAnexus Titan for data analysis, and DNAnexus Portals, which create secure online workspaces for collaborative projects. Additionally, the Clinico-Genomic Data Solution aims to enhance disease-specific datasets through partnerships with healthcare providers, improving screening and treatment pathways for complex diseases. DNAnexus serves a diverse clientele, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.
Emulate, Inc. specializes in developing organs-on-chips technology that emulates human biology to better understand the effects of diseases, medications, and environmental factors on human health. The company offers organ-chips that replicate the functions of various organs, including the lung, intestine, liver, and skin, and can simulate both normal and disease states. Emulate’s platform aims to provide more accurate predictions of human responses compared to traditional experimental methods, such as cell cultures or animal testing. The company serves a diverse clientele that includes biotechnology and pharmaceutical firms, consumer health and cosmetics companies, government agencies, and academic researchers. Founded in 2013 and based in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. It has shifted its focus towards advancing product innovation and safety across multiple sectors, including drug development and personalized medicine.
SpeeDx is a company that specializes in molecular diagnostic solutions aimed at enhancing patient management through comprehensive information. Utilizing innovative real-time polymerase chain reaction (qPCR) technology, SpeeDx offers a leading portfolio of multiplex diagnostic tests. These tests are particularly focused on sexually transmitted infections (STIs), antibiotic resistance markers, and respiratory diseases. By employing advanced multiplex detection and priming strategies, SpeeDx enables healthcare providers to effectively diagnose infectious diseases and assess antibiotic resistance, ultimately improving clinical outcomes.
Intabio, Inc. is a biotechnology company focused on enhancing the development and manufacturing processes of biotherapeutic drugs through its innovative analytical solutions. Founded in 2015 and based in Newark, California, Intabio has developed the Blaze system, which includes a bench-top instrument, microfluidic chip, and reagent kit designed for the separation, quantitation, and molecular mass identity analysis of intact biotherapeutic proteins. This platform enables real-time characterization of protein isoforms, allowing for the identification of structural modifications that may affect drug efficacy and safety. By providing early product quality characterization and improving throughput, the Blaze system addresses critical challenges faced by biopharmaceutical developers, who often encounter limitations with traditional testing methods. Intabio's technology integrates multiple analytical techniques to facilitate a comprehensive analysis of biologics, ultimately streamlining the development process and reducing the risk of costly delays and missteps.
Vizgen, Inc. is a biotechnology company that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. The company's flagship technology, MERFISH, utilizes multiplexed single-molecule imaging to accurately measure the quantity and spatial distribution of RNA within individual cells. This innovative approach facilitates single-cell gene expression profiling in intact tissue slices, providing valuable insights into various applications, including oncology, immunology, neuroscience, infectious disease, and regenerative medicine. Established in 2019 and based in Cambridge, Massachusetts, Vizgen is committed to advancing research by enabling high-throughput and cost-effective analysis of complex biological systems at a cellular level.
Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, established in 2016. The company specializes in developing rapid tests that analyze the immune system to address significant clinical and public health challenges, particularly in the diagnosis of acute bacterial and viral infections, as well as sepsis. Utilizing patent-pending biomarkers exclusively licensed from Stanford University, Inflammatix aims to create clinically actionable results through proprietary machine-learning algorithms. In addition to its focus on acute infections and sepsis, the company is expanding its diagnostics pipeline to include tests for tropical infections, autoimmune diseases, transplant rejection, and other medical conditions, ultimately assisting healthcare providers in making informed diagnostic decisions.
IsoPlexis Corp is a life sciences company based in Branford, Connecticut, that specializes in developing a diagnostic platform designed to measure cellular immune responses in patients. Founded in 2013, the company's technology focuses on single-cell detection, allowing for the identification of diverse immune responses at the individual cell level. This platform plays a crucial role in assessing the safety and efficacy of therapeutics, as well as monitoring disease progression. By providing detailed insights into immune responses, IsoPlexis aims to enhance therapeutic development and inform clinical decision-making for healthcare professionals.
IsoPlexis Corp is a life sciences company based in Branford, Connecticut, that specializes in developing a diagnostic platform designed to measure cellular immune responses in patients. Founded in 2013, the company's technology focuses on single-cell detection, allowing for the identification of diverse immune responses at the individual cell level. This platform plays a crucial role in assessing the safety and efficacy of therapeutics, as well as monitoring disease progression. By providing detailed insights into immune responses, IsoPlexis aims to enhance therapeutic development and inform clinical decision-making for healthcare professionals.
SGI-DNA provides a variety of synthetic genomic solutions to advance your research. Our comprehensive suite of genomic services will allow you to discover, design, and build the sequences you need. We are committed to reducing barriers associated with DNA synthesis and sequence analysis by leveraging the technology developed at the J. Craig Venter Institute and Synthetic Genomics, Inc. SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc (SGI), was founded in 2013 and is headquartered in La Jolla, CA. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Ham Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers a comprehensive suite of genomic services, including whole genome sequencing, library design, and other bioinformatics services. SGI-DNA is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers.
ChromaCode, Inc. is a molecular diagnostics company based in Carlsbad, California, that specializes in developing innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) using proprietary technology derived from Caltech. The company enhances the performance of quantitative polymerase chain reaction (qPCR) instruments, achieving a five-fold increase in multiplexing capabilities while maintaining cost-effectiveness. ChromaCode employs advanced bioinformatics techniques and patented mathematical methods to improve signal processing, enabling laboratories to conduct comprehensive testing of multiple targets in a single sample. Additionally, the company offers products such as the HDPCR Tick-Borne Pathogen Panel, which detects various tick-borne pathogens through a multiplex polymerase chain reaction test. Founded in 2012, ChromaCode draws expertise from professionals with backgrounds in leading organizations such as Illumina and Google[x].
Intabio, Inc. is a biotechnology company focused on enhancing the development and manufacturing processes of biotherapeutic drugs through its innovative analytical solutions. Founded in 2015 and based in Newark, California, Intabio has developed the Blaze system, which includes a bench-top instrument, microfluidic chip, and reagent kit designed for the separation, quantitation, and molecular mass identity analysis of intact biotherapeutic proteins. This platform enables real-time characterization of protein isoforms, allowing for the identification of structural modifications that may affect drug efficacy and safety. By providing early product quality characterization and improving throughput, the Blaze system addresses critical challenges faced by biopharmaceutical developers, who often encounter limitations with traditional testing methods. Intabio's technology integrates multiple analytical techniques to facilitate a comprehensive analysis of biologics, ultimately streamlining the development process and reducing the risk of costly delays and missteps.
General Automation Lab Technologies, Inc. specializes in developing and commercializing microbiological technologies that enhance the study of bacteria and other microbes. The company offers the GALT Prospector, a high-throughput isolation and cultivation array system designed for microbial research. This platform enables scientists to access a diverse range of microbes and isolate rare or unique species, facilitating deeper insights into their functions. The applications of its microbe systems span various fields, including agriculture, human health, environmental science, and industrial processes. Established in 2014, General Automation Lab Technologies is headquartered in San Carlos, California, and aims to advance microbiome science through innovative technologies.
SGI-DNA provides a variety of synthetic genomic solutions to advance your research. Our comprehensive suite of genomic services will allow you to discover, design, and build the sequences you need. We are committed to reducing barriers associated with DNA synthesis and sequence analysis by leveraging the technology developed at the J. Craig Venter Institute and Synthetic Genomics, Inc. SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc (SGI), was founded in 2013 and is headquartered in La Jolla, CA. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Ham Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers a comprehensive suite of genomic services, including whole genome sequencing, library design, and other bioinformatics services. SGI-DNA is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers.
SeLux Diagnostics, Inc. is focused on advancing antibiotic susceptibility testing and infectious disease diagnostics through its innovative phenotyping platform. Founded in 2014 and located in Charlestown, Massachusetts, the company employs a unique synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing. This platform significantly improves the accuracy and timeliness of diagnosing infections, enabling healthcare providers to prescribe targeted and personalized antibiotic therapies. By facilitating informed treatment decisions, SeLux Diagnostics aims to enhance patient care, save lives, and improve overall health outcomes in hospital settings.
SpeeDx is a company that specializes in molecular diagnostic solutions aimed at enhancing patient management through comprehensive information. Utilizing innovative real-time polymerase chain reaction (qPCR) technology, SpeeDx offers a leading portfolio of multiplex diagnostic tests. These tests are particularly focused on sexually transmitted infections (STIs), antibiotic resistance markers, and respiratory diseases. By employing advanced multiplex detection and priming strategies, SpeeDx enables healthcare providers to effectively diagnose infectious diseases and assess antibiotic resistance, ultimately improving clinical outcomes.
SpeeDx is a company that specializes in molecular diagnostic solutions aimed at enhancing patient management through comprehensive information. Utilizing innovative real-time polymerase chain reaction (qPCR) technology, SpeeDx offers a leading portfolio of multiplex diagnostic tests. These tests are particularly focused on sexually transmitted infections (STIs), antibiotic resistance markers, and respiratory diseases. By employing advanced multiplex detection and priming strategies, SpeeDx enables healthcare providers to effectively diagnose infectious diseases and assess antibiotic resistance, ultimately improving clinical outcomes.
Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2015. The company specializes in manufacturing reagents for tissue imaging and multiplexing detection, primarily serving the life science and biomedical research communities. Ultivue offers advanced technologies such as DNA-PAINT and DNA-Exchange, which facilitate the collection of high-resolution microscopic images. These innovations are aimed at enhancing the understanding of biological processes and medical diagnostics. The company’s products are designed for use in fluorescent microscopy-based research and are expected to have future applications in clinical diagnostics.
IsoPlexis Corp is a life sciences company based in Branford, Connecticut, that specializes in developing a diagnostic platform designed to measure cellular immune responses in patients. Founded in 2013, the company's technology focuses on single-cell detection, allowing for the identification of diverse immune responses at the individual cell level. This platform plays a crucial role in assessing the safety and efficacy of therapeutics, as well as monitoring disease progression. By providing detailed insights into immune responses, IsoPlexis aims to enhance therapeutic development and inform clinical decision-making for healthcare professionals.
Scipher Medicine is a biotechnology company based in Waltham, Massachusetts, that focuses on developing a molecular technology platform to predict patient responses to drug therapies, particularly in cardiovascular and autoimmune diseases. The company offers several diagnostic tests, including PrismDx, which identifies patients who may not respond to specific medications, PrismRA for patients with rheumatoid arthritis, and PrismUC for those with ulcerative colitis. These tests enable healthcare providers to prescribe more suitable alternative therapies for patients who are unlikely to benefit from traditional treatments. Scipher Medicine emphasizes the importance of providing scientifically backed data to improve patient outcomes and enhance treatment decisions. The company has also established a strategic partnership with Ambry Genetics Corporation to further advance its capabilities. Founded in 2014, Scipher Medicine was previously known as DZZOM Delaware Corporation before changing its name in 2015.
908 Devices Inc. is a Boston-based company that develops and sells advanced measurement devices for chemical and biochemical analysis, utilizing mass spectrometry technology. The company's product lineup includes handheld and desktop devices designed for immediate, on-site analysis across various fields such as life sciences, bioprocessing, industrial biotechnology, and forensics. Notable products include the MX908, a portable mass spectrometry device for rapid analysis of unknown substances, the Rebel desktop analyzer for real-time monitoring of bioprocess environments, and the ZipChip, a high-resolution separation platform that enhances mass spectrometry sample analysis. Established in 2012, 908 Devices aims to make mass spectrometry accessible beyond traditional laboratories, providing reliable tools for professionals needing quick and actionable insights. The company operates mainly in the United States while also serving markets in Europe, Asia, and beyond.
Sherlock Biosciences, Inc., a biotechnology company, develops molecular diagnostics solutions. It offers SHERLOCK, a CRISPR-based method to detect and quantify specific genetic sequences, and INSPECTR, a synthetic biology-based molecular diagnostics platform. The company offers its products in the areas of precision oncology, infection identification, food safety, at-home tests, and disease detection. The company was incorporated in 2018 and is based in Cambridge, Massachusetts.
Deep Lens is a provider of a digital pathology workflow platform intended to allow pathology groups to collaborate on groundbreaking cancer research. The company's platform includes AI-powered image detection and workflow support, collaboration, cloud storage, and built-in APIs for the ingestion of third-party AI models and integration to EMR, LIMS, and other systems, helping patients, pathologists, and physicians work together to accelerate and optimize treatment.
Founded in 2017, Deep Lens is headquartered in Columbus, Ohio.
Candel develops cancer immunotherapies designed to improve the lives of cancer patients and their families. The company's immunotherapies focus on preventing the recurrence and progression of cancer with low toxicity level which is well suited for the treatment of less aggressive or slower growing cancers such as newly diagnosed prostate cancer, enabling physicians to ensure improved outcomes for their patients and help them recover faster.
Teckro, Inc. offers a solution that transforms clinical trials making all relevant information instantly accessible to every active member of the study. The company facilitates connections between investigators and the expertise they need; and helps study teams, sites, and patients to connect. Its solution instantly captures and shares team’s knowledge to dramatically reduce the burden on CRAs, medical monitors, data management, and study personnel. The company serves pharmaceutical companies and clinical researchers across the world. Teckro, Inc. was incorporated in 2015 and is based in Limerick, Ireland.
SeLux Diagnostics, Inc. is focused on advancing antibiotic susceptibility testing and infectious disease diagnostics through its innovative phenotyping platform. Founded in 2014 and located in Charlestown, Massachusetts, the company employs a unique synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing. This platform significantly improves the accuracy and timeliness of diagnosing infections, enabling healthcare providers to prescribe targeted and personalized antibiotic therapies. By facilitating informed treatment decisions, SeLux Diagnostics aims to enhance patient care, save lives, and improve overall health outcomes in hospital settings.
Intabio, Inc. is a biotechnology company focused on enhancing the development and manufacturing processes of biotherapeutic drugs through its innovative analytical solutions. Founded in 2015 and based in Newark, California, Intabio has developed the Blaze system, which includes a bench-top instrument, microfluidic chip, and reagent kit designed for the separation, quantitation, and molecular mass identity analysis of intact biotherapeutic proteins. This platform enables real-time characterization of protein isoforms, allowing for the identification of structural modifications that may affect drug efficacy and safety. By providing early product quality characterization and improving throughput, the Blaze system addresses critical challenges faced by biopharmaceutical developers, who often encounter limitations with traditional testing methods. Intabio's technology integrates multiple analytical techniques to facilitate a comprehensive analysis of biologics, ultimately streamlining the development process and reducing the risk of costly delays and missteps.
Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, established in 2016. The company specializes in developing rapid tests that analyze the immune system to address significant clinical and public health challenges, particularly in the diagnosis of acute bacterial and viral infections, as well as sepsis. Utilizing patent-pending biomarkers exclusively licensed from Stanford University, Inflammatix aims to create clinically actionable results through proprietary machine-learning algorithms. In addition to its focus on acute infections and sepsis, the company is expanding its diagnostics pipeline to include tests for tropical infections, autoimmune diseases, transplant rejection, and other medical conditions, ultimately assisting healthcare providers in making informed diagnostic decisions.
NanoView Biosciences is a biotechnology company based in Boston, Massachusetts, specializing in the characterization of extracellular vesicles, particularly exosomes. Utilizing its proprietary ExoView technology, the company provides high-throughput, cost-effective analysis solutions that facilitate the detection and multiparametric characterization of exosomes from complex biological samples such as whole blood, serum, plasma, and urine. NanoView Biosciences offers a range of products, including the ExoView R100 and ExoView Tetraspanin, as well as custom assays and sample services. The company's innovations support research and the advancement of precision medicine, enabling life science researchers to gain insights into the biological roles of exosomes as potential biomarkers for disease diagnosis, treatment, and monitoring. Founded in 2015, NanoView Biosciences is committed to enhancing the understanding of exosomes in the context of health and disease.
General Automation Lab Technologies, Inc. specializes in developing and commercializing microbiological technologies that enhance the study of bacteria and other microbes. The company offers the GALT Prospector, a high-throughput isolation and cultivation array system designed for microbial research. This platform enables scientists to access a diverse range of microbes and isolate rare or unique species, facilitating deeper insights into their functions. The applications of its microbe systems span various fields, including agriculture, human health, environmental science, and industrial processes. Established in 2014, General Automation Lab Technologies is headquartered in San Carlos, California, and aims to advance microbiome science through innovative technologies.
Farcast is a clinical diagnostic company dedicated to providing personalized cancer treatment solutions. Its core technology utilizes a human tumor microenvironment to enable oncologists and drug developers to assess individual tumors and determine their treatment response profiles. This innovative approach aims to surpass traditional biomarker-guided strategies, thereby enhancing access to personalized medicine and improving the clinical management of cancer. Headquartered in Boston, Massachusetts, Farcast also operates a laboratory in Bangalore, India, reflecting its commitment to advancing cancer care through cutting-edge technology.
DiCE Therapeutics, founded in 2013 and based in Menlo Park, California, specializes in developing a platform for the discovery of novel small molecules aimed at targets that have previously been difficult to address in the pharmaceutical sector. The company utilizes innovative technology that extends directed evolution, allowing for the direct translation of DNA-encoded information into organic compounds, thereby streamlining the traditionally labor-intensive processes of medicinal chemistry. This platform not only serves the pharmaceutical industry but also has applications in agriculture and materials sciences. The founding team includes notable figures such as Stanford Professor Pehr Harbury, who developed the core technology, and other experienced professionals from various sectors, contributing to the company's mission of transforming drug discovery and development.
SeLux Diagnostics, Inc. is focused on advancing antibiotic susceptibility testing and infectious disease diagnostics through its innovative phenotyping platform. Founded in 2014 and located in Charlestown, Massachusetts, the company employs a unique synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing. This platform significantly improves the accuracy and timeliness of diagnosing infections, enabling healthcare providers to prescribe targeted and personalized antibiotic therapies. By facilitating informed treatment decisions, SeLux Diagnostics aims to enhance patient care, save lives, and improve overall health outcomes in hospital settings.